cardinal health - Search News

Citi raises Cardinal Health stock target to $130

Cardinal Health Inc (CAH) Q2 2025 Earnings Call Highlights: Strong Pharma Growth Amid Revenue ...

Cardinal Health Inc (CAH) raises EPS guidance despite a 4% revenue decline, driven by robust pharmaceutical segment performance and strategic acquisitions.

Investing.com on MSN · 12h

Citi raises Cardinal Health stock target to $130 on Pharma strength

Citi analyst Daniel Grosslight increased the price target for Cardinal Health (NYSE:CAH) shares to $130 from the previous $129, while keeping a Neutral rating on the stock. The adjustment follows Cardinal Health's recent financial performance,

Drug Store News · 20h

Cardinal Health reports Q2 results, raises fiscal year 2025 outlook

Cardinal Health's pharmaceutical and specialty solutions segment profit increased 7% to $531 million in the second quarter.

Business Insider · 23h

Cardinal Health raises FY25 EPS view to $7.85-$8.00 from $7.75-$7.90

Consensus $7.86. The company said, “The company raised its fiscal 2025 guidance range for non-GAAP diluted earnings per share attributable to

Hosted on MSN · 16h

Cardinal Health raises FY25 EPS guidance to $7.85-$8 amid specialty growth and acquisitions

Q2 2025 Management View CEO Jason Hollar emphasized strong Q2 performance driven by robust demand in Pharmaceutical and Specialty Solutions, particularly in brand, specialty, generics, and consumer health segments.

Cardinal Health’s Strong Performance and Strategic Acquisitions Justify Buy Rating

Mizuho Securities analyst Steven Valiquette has reiterated their bullish stance on CAH stock, giving a Buy rating yesterday.Invest with ...

Modern Healthcare17h

Cardinal Health CEO Jason Hollar issues warning on tariffs

Cardinal Health warned Thursday that if President Donald Trump follows through with threatened tariffs next month, higher ...

23h

Cardinal Health lifts 2025 profit forecast on specialty drugs demand

Drug distributor Cardinal Health on Thursday raised its fiscal 2025 adjusted profit forecast as strong demand for costly specialty medicines and branded drugs drove sales at its pharmaceuticals unit.

Cardinal Health (NYSE:CAH) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Cardinal Health (NYSE:CAH – Get Free Report) had its target price hoisted by equities researchers at Wells Fargo & Company from $127.00 to $135.00 in a research note issued on Wednesday,Benzinga ...

Hoodline17h

Dublin City Schools Abandons Cardinal Health Building Purchase, Opts for Scioto High School Expansion

Dublin City Schools has officially backed out of a deal to acquire the vacant Cardinal Health office building, pivoting ...

Positive Financial Prospects Drive Buy Rating for Cardinal Health Amid Raised Guidance and Strong Segment Performance

Charles Rhyee, an analyst from TD Cowen, maintained the Buy rating on Cardinal Health (CAH – Research Report). The associated price target was ...

MDM17h

Cardinal Health 2Q Sales Rise 16% Outside of Optimum Impact

Cardinal Health reported an increase in revenue for two of its segments, while the departure of Optimum impacted its Pharmaceuticals segment.

17h

Cardinal Health, Inc. (CAH) Q2 2025 Earnings Call Transcript

Hello, and welcome to the Second Quarter Fiscal Year 2025 Cardinal Health Inc. Earnings Conference Call. My name is George, and I'll be coordinator for today's event. Please note, this conference is ...

Zacks.com on MSN18h

CAH Q2 Earnings and Sales Beat Estimates, 2025 EPS View Raised

Cardinal Health, Inc. CAH reported second-quarter fiscal 2025 adjusted earnings per share (EPS) of $1.93, which beat the ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Citi raises Cardinal Health stock target to $130

Related topics